TCB Capital Advisors

We are excited to share that TCB Capital Advisors has been featured in a new industry white paper from Citeline: Clinical Trial Disclosure Noncompliance: What Is Its Impact on Pharma M&As?   The report explores how transparency in clinical trial reporting directly impacts M&A activity and early-stage financings in pharma and biotech. It highlights the increasing importance of rigorous diligence and trustworthy data as key drivers of successful transactions.   Our President & Managing Director, Sam Libby, contributed insights on the role of transparency and diligence in building lasting investor confidence. We are proud to see TCB’s perspective represented alongside other industry leaders and look forward to continuing to advance conversations at the intersection of science, capital, and patient impact. https://lnkd.in/eR5rr9ga

Excited to share that Sam Libby, recently joined Passionate Pioneers with Mike Biselli for a conversation on how TCB Capital Advisors is working to redefine healthcare investment banking.   In the episode, Sam discusses: -Why TCB prioritizes patient-first partnerships -Our three-vertical model that combines banking, clinical/scientific, and commercial expertise -How we are supporting innovators in oncology, women’s health, and neurodegenerative disease -The future of predictive medicine, including AI-powered diagnostic tools like Clairity’s breast cancer risk assessment   A big thank you to Mike Biselli for hosting this thoughtful discussion and for shining a light on the urgent need to transform how capital supports healthcare innovation.   https://lnkd.in/eufZ82GB    

We are excited to share that our President & Managing Director, Sam Libby, joined the Talk to Your Pharmacist podcast hosted by Hillary Blackburn, PharmD, MBA.   Sam brings a wealth of experience in guiding innovative healthcare companies through pivotal growth and strategic moments. In the episode, he dives into: -His journey from growing up the son of two therapists to co-founding TCB Capital Advisors -Insights on the healthcare investment landscape across oncology, neurodegenerative disease, women’s health, and digital health -The balance between financial strategy and patient access in shaping the future of care -Where he sees the biggest opportunities for healthcare innovation over the next decade   At TCB, our mission is to partner with founders and innovators advancing patient-first solutions – Sam’s conversation highlights why we believe this work matters now more than ever. https://lnkd.in/ei45Vk6Z

October marks Breast Cancer Awareness Month – a time to reflect on progress, but also on the work that still lies ahead.   Despite decades of research, advocacy, and investment, over one-third of women in the U.S. are still diagnosed at Stage 3 or later. Late detection not only impacts survival rates but also drives treatment costs that are nearly 3x higher compared to diagnoses at Stage 1.   At TCB Capital Advisors, we are proud to support innovators like Clairity, Inc., the first and only FDA-authorized AI prognostic platform that transforms a routine mammogram into a five-year breast cancer risk score. By identifying hidden risk earlier, Clairity is helping health systems, payers, and women themselves shift the paradigm from late detection to prevention and proactive care.   This month – and every month – we stand with the millions of women and families affected by breast cancer, and we are committed to advancing solutions that bring earlier detection, equitable access, and better outcomes to the forefront.

Great to see an innovative company like Altoida, Inc. highlighted in Being Patient. Altoida’s platform is poised to revolutionize neurodegenerative disease detection by moving from outdated pen-and-paper tests toward scalable digital biomarkers that can detect cognitive impairment at stages traditional tools miss. This is not just an incremental improvement – it is the kind of transformation that can fundamentally reshape patient pathways and accelerate intervention in Alzheimer’s disease and beyond.   We are proud to support Altoida as they continue to set new standards in neurodegenerative care and demonstrate how thoughtful application of technology can drive real patient impact

We are proud to share Clairity, Inc.’s recent feature in The Wall Street Journal which highlights its pioneering work in breast cancer risk prediction.   Clairity’s FDA-authorized AI platform is the first of its kind to predict a woman’s 5-year risk of developing breast cancer directly from a routine mammogram. By unlocking subtle imaging patterns invisible to the human eye, Clairity is redefining how clinicians can identify at-risk women earlier, enabling proactive care and better outcomes.   This recognition underscores the transformative role AI is beginning to play in cancer prevention and precision health – and Clairity is leading the way.   At TCB Capital Advisors, we are honored to support Clairity on its mission to make breast cancer risk prediction more accurate, equitable, and accessible for women everywhere. https://lnkd.in/euQAjPza

We are proud to share that our own Sam Libby recently joined James Zanewicz, JD, LLM, RTTP on the BIO from the BAYOU podcast. The conversation centered on what it truly means to build patient-centered biotech deals. Sam and James discussed how clinical data, strategy, and timing shape sustainable healthcare companies, the common mistakes startups make when pitching to investors, and why mission alignment must be at the core of healthcare innovation. At TCB Capital Advisors, we believe the future of healthcare will be shaped by mission-driven founders who understand that patients are more than a collection of symptoms. Conversations like this remind us why we are so committed to supporting companies that are transforming care pathways across oncology, women’s health, neurodegenerative disease, and beyond. Catch the full episode below - a fantastic discussion on what it takes to reimagine healthcare innovation. https://lnkd.in/eNBj7F7q

TCB Capital Advisors congratulates Nishant Sachdev on his recent promotion to Partner and Managing Director. Nishant's passion for impacting patient outcomes and dedication to our clients has been exceptional. We celebrate his advancement to the role of Partner and Managing Director and are excited to see the additional impact he drives for our clients. 

We want to highlight two amazing companies poised to change care for millions across the globe that will be taking the stage at #LSIEurope25 in London next week. Altoida, Inc. and Clairity, Inc. are leveraging the power of AI to tackle some of the most pressing challenges in healthcare and reshape care pathways for patients globally.   Marc Jones, CEO of Altoida, will present the company’s FDA-bound digital biomarker platform designed to transform how neurodegenerative diseases are detected, monitored, and treated. Altoida’s innovative platform demonstrates a pathway to diagnosis before disease progression limits treatment options. Jeffrey R. Luber, CEO of Clairity, will highlight the first FDA De Novo–authorized AI platform for predicting breast cancer risk directly from a standard mammogram – a breakthrough that could redefine early detection and prevention for millions of women globally.   TCB Capital Advisors is proud to support both teams as they advance solutions in areas where innovation is critically needed: neurodegenerative disease and breast cancer. If you will be attending the conference, make sure to check out their sessions and connect with Marc and Jeff to hear firsthand about the impact their platforms are making.

We are excited to share that Sam Libby recently joined Prashant Choubey on the VC10X Podcast for a thoughtful discussion on the future of healthcare innovation. Sam spoke about the revolution in predictive medicine and how the industry is shifting from diagnosing disease to proactively predicting risk before patients get sick. He also shared perspectives on building patient-first companies in today’s tough market and the role of AI in empowering clinicians while enabling more holistic, personalized care.   This conversation is a great listen for anyone interested in further exploring the intersection of healthcare, technology, and venture capital. Catch the full episode on YouTube, Spotify, or Apple Podcasts (YouTube link below).   https://lnkd.in/e76wDkDv   #Healthcare #HealthTech #VentureCapital #Podcast #AIinHealthcare #DigitalHealth #PatientCare #Innovation